Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery
Status:
Withdrawn
Trial end date:
2011-10-17
Target enrollment:
Participant gender:
Summary
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in
chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Ixabepilone may also make
tumor cells more sensitive to radiation therapy. Giving radiation therapy with chemotherapy
after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase I/II trial is studying the side effects and best dose of ixabepilone when
given together with radiation therapy to see how well it works in treating patients with
high-risk stage III prostate cancer after surgery.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Simmons Cancer Center University of Texas Southwestern Medical Center